Published in Blood on January 29, 2013
AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell (2014) 2.33
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med (2015) 1.66
Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology (2014) 1.59
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
Emerging therapeutic drugs for AML. Blood (2015) 1.04
Selective inhibitors of protein methyltransferases. J Med Chem (2014) 1.01
The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle. Cell Cycle (2014) 0.97
Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol (2015) 0.93
Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol (2014) 0.90
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood (2016) 0.87
Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol (2015) 0.87
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica (2015) 0.85
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One (2014) 0.85
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov (2016) 0.85
Pediatric AML: From Biology to Clinical Management. J Clin Med (2015) 0.85
Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp Hematol (2014) 0.84
Murine models of acute leukemia: important tools in current pediatric leukemia research. Front Oncol (2014) 0.84
The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. Mol Cell (2015) 0.84
Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev (2015) 0.83
Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia (2013) 0.82
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target. Am J Cancer Res (2015) 0.82
Targeted drug discovery for pediatric leukemia. Front Oncol (2013) 0.82
Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol (2015) 0.81
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma (2014) 0.81
Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression. Nat Commun (2015) 0.81
Treatment of infant leukemias: challenge and promise. Hematology Am Soc Hematol Educ Program (2013) 0.80
Next generation sequencing of acute myeloid leukemia: influencing prognosis. BMC Genomics (2015) 0.80
AF4 uses the SL1 components of RNAP1 machinery to initiate MLL fusion- and AEP-dependent transcription. Nat Commun (2015) 0.79
The upstreams and downstreams of H3K79 methylation by DOT1L. Chromosoma (2016) 0.79
Drug development: target practice. Nature (2013) 0.79
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest (2016) 0.78
Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica (2016) 0.78
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene (2016) 0.77
Epigenetics of hematopoiesis and hematological malignancies. Genes Dev (2016) 0.77
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget (2016) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis. Oncotarget (2016) 0.76
Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia. Oncotarget (2016) 0.76
Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Mol Cell Oncol (2014) 0.75
Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells. Oncotarget (2016) 0.75
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach. ACS Med Chem Lett (2017) 0.75
Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. J Clin Invest (2017) 0.75
The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia. Cancers (Basel) (2017) 0.75
Transcriptional Addiction in Cancer. Cell (2017) 0.75
Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance. Mod Pathol (2016) 0.75
Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L. Eur J Drug Metab Pharmacokinet (2017) 0.75
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. Mol Clin Oncol (2017) 0.75
GenePattern 2.0. Nat Genet (2006) 29.07
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell (2010) 4.99
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
The critical role of chromosome translocations in human leukemias. Annu Rev Genet (1998) 3.49
A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell (2010) 3.47
Afadin: A novel actin filament-binding protein with one PDZ domain localized at cadherin-based cell-to-cell adherens junction. J Cell Biol (1997) 2.82
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev (2010) 2.53
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev (2008) 2.41
The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells. J Cell Biol (1997) 2.10
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 1.88
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res (2010) 1.77
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood (2011) 1.74
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc (2011) 1.66
The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol (2005) 1.45
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2012) 1.36
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartment. J Cell Physiol (2007) 0.90
PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget (2010) 0.89
Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. Blood (2010) 0.88
MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia (2011) 0.88
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Coordinated regulation of Arabidopsis thaliana development by light and gibberellins. Nature (2008) 4.71
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2003) 4.44
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 3.89
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.66
Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov (2009) 3.50
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A (2011) 3.38
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Histone deacetylase inhibitors. Adv Cancer Res (2004) 2.93
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
Histone deacetylases. Curr Opin Pharmacol (2003) 2.58
Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol (2013) 2.39
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 2.26
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12
Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol (2005) 2.07
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood (2003) 1.92
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther (2006) 1.84
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Photon-counting gamma camera based on columnar CsI(Tl) optically coupled to a back-illuminated CCD. Proc SPIE Int Soc Opt Eng (2007) 1.62
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res (2009) 1.54
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A (2012) 1.52
Kinetic characterization of a novel cationic (99m)Tc(I)-tricarbonyl complex, (99m)Tc-15C5-PNP, for myocardial perfusion imaging. J Nucl Cardiol (2010) 1.50
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res (2009) 1.48
Diurnal Pattern of Tear Osmolarity and Its Relationship to Corneal Thickness and Deswelling. Cornea (2013) 1.46
Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proc Natl Acad Sci U S A (2012) 1.45
Experimental determination of object statistics from noisy images. J Opt Soc Am A Opt Image Sci Vis (2003) 1.43
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett (2011) 1.42
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell (2013) 1.42
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res (2009) 1.40
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol (2004) 1.40
Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res (2004) 1.39
CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood (2007) 1.39
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood (2013) 1.38
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther (2014) 1.37
Optimism, social support and psychosocial functioning among women with breast cancer. Psychooncology (2006) 1.35
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res (2008) 1.33
Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood (2011) 1.32
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood (2002) 1.30
Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol (2010) 1.27
Medical and psychosocial predictors of delay in seeking medical consultation for breast symptoms in women in a public sector setting. J Behav Med (2006) 1.27
Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev (2012) 1.26
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res (2007) 1.24
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 1.23
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res (2011) 1.23
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol (2013) 1.23
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood (2006) 1.22
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res (2011) 1.18
Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood (2007) 1.18